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ABSTRACT
MYC deregulation is a driver of many human cancers. Altering the balance of MYC 
protein levels at the level of transcription, protein stability, or turnover is sufficient 
to transform cells to a tumorigenic phenotype. While direct targeting of MYC is 
difficult, specific genetic vulnerabilities of MYC-deregulated cells could be exploited 
to selectively inhibit their growth. Using a genome-wide shRNA screen, we identified 
78 candidate genes, which are required for survival of human mammary epithelial 
cells with elevated MYC levels. Among the candidates, we validated and characterized 
FBXW7, a component of the SCF-like ubiquitin ligase complex that targets MYC 
for proteasomal degradation. Down-regulation of FBXW7 leads to synergistic 
accumulation of cellular and active chromatin-bound MYC, while protein levels of 
other FBXW7 targets appear unaffected. Over a four-week time course, continuous 
FBXW7 down-regulation and MYC activation together cause an accumulation of cells 
in S-phase and G2/M-phase of the cell cycle. Under these conditions, we also observe 
elevated chromatin-bound levels of CDC45, suggesting increased DNA replication 
stress. Consistent with these results, FBXW7 down-regulation alone decreases the 
survival of T47D breast cancer cells. These results establish that FBXW7 down-
regulation is synthetic lethal with MYC, and that MYC is a critical target of FBXW7 in 
breast epithelial cells.
INTRODUCTION
Genetic and epigenetic events altering the 
expression, the stability, or the activity of oncogenes and 
tumor suppressor genes participate in the initiation and 
maintenance of human cancers [1]. Among the genes 
which expression is modified in cancer, only a relatively 
small subset is recurrently altered and contributes to the 
tumorigenic phenotype [2]. Identification of such “cancer 
driver genes” has facilitated the development of targeted 
treatment options in the recent years, yet there are still 
pharmacological limitations that hinder direct targeting of 
some major cancer drivers including MYC [3].
The MYC proto-oncogene is deregulated in over 
half of human cancers including hematopoietic cancers, 
sarcomas, and carcinomas [4]. MYC is essential for 
normal cell growth. In particular, MYC is required for 
cell proliferation and is involved in differentiation, 
metabolism, and apoptosis, most notably through its 
function as a bHLH-LZ transcriptional activator and 
repressor [5]. In addition, MYC has direct, transcription-
independent functions in DNA replication [6] and protein 
synthesis [7], further supporting its major role in cellular 
homeostasis. Therefore, cellular MYC protein levels are 
tightly controlled through regulated expression [8], protein 
stability [9], and degradation [10]. Indeed, alterations 
in MYC abundance are a critical component of MYC-
dependent tumorigenesis [11]. 
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At least 4 different ubiquitin ligase complexes can 
target MYC for proteasomal degradation [10], including 
the SCF-like ligase complex containing FBXW7 [12, 13]. 
FBXW7 (or Fbw7, Sel-10, hCdc4, hAgo) is an F-box 
protein that confers substrate specificity for this complex 
[14]. MYC is a documented target of FBXW7. However, 
FBXW7 also targets several additional oncoproteins and 
master regulator molecules including CyclinE, NOTCH1, 
mTOR, SREBP, and c-JUN, among others [14] and the 
respective contributions of FBXW7-dependent regulation 
of these proteins towards abnormal cell growth is not 
known. Moreover, although the role of FBXW7 as a tumor 
suppressor is well documented in hematopoietic tumors 
in which mutations in FBXW7 are unequivocally linked 
to tumorigenesis [15], this is not as clear for other cancer 
types [16, 17]. For example, it has been reported that the 
inactivation of FBXW7 can be associated with favorable 
prognosis in a subset of breast cancers [18], suggesting 
that the physiological role of FBXW7 and consequences 
of its loss may be dependent on cell types and contexts. 
Exploring synthetic lethality has provided many 
critical insights into the biology of oncogenes [19]. In 
addition, identifying genes that are essential to cope with 
activated oncogenes might provide alternatives to direct 
targeting for cancer therapy [20]. In the case of MYC, 
several genes which loss is synthetic lethal with aberrant 
MYC expression have been identified. These include DR5 
in the death receptor pathway [21], the WRN helicase [22, 
23], the AuroraA/B [24] and CDK [25, 26] cell-cycle 
kinases, and Chk1/2 [27, 28]. More recently, genome-wide 
approaches have helped to identify the SAE1/2-dependent 
SUMOylation pathway [29] and CSNK1E kinase [30] as 
potential synthetic lethal candidates as well. Intriguingly, 
studies in different model systems appear to yield unique 
results, possibly due to MYC’s cell-context specific roles 
and the differing modes of deregulation.
In the present study, we conducted a genome-
wide screen to identify genes that are required to survive 
MYC overexpression in MCF10A breast epithelial cells 
conditionally expressing a MYCER allele. We document 
these synthetic lethal interactions and identify 78 potential 
synthetic lethal targets. Among these, we have validated 
the F-box protein FBXW7 as a synthetic lethal candidate 
in MCF10A-MYCER cells overexpressing MYC. We 
show that shRNA-mediated knockdown of FBXW7 
confers increased lethality to non-transformed MCF10A 
cells with activated MYCER and to T47D breast cancer 
cells. In MCF10A, active chromatin-bound MYCER is 
stabilized in cells with down-regulated FBXW7, while 
protein stability of other FBXW7 targets is not affected. 
We also find that knockdown of FBXW7 upon MYCER 
activation results in accumulation of cells in S/G2 phase 
with increased chromatin-bound CDC45. These results 
suggest that increased cellular MYCER levels as a result 
of FBXW7 loss yields sufficient cellular stress to confer 
selective lethality to those cells with deregulated MYC.
RESULTS
MCF10A-MYCER cells: a model for MYC 
deregulation 
First, we sought to generate a cellular model for 
MYC conditional expression that recapitulates MYC 
deregulation in human cancer cells. To this goal, we 
stably integrated an inducible MYCER transgene [31] 
into MCF10A, a non-transformed breast epithelial cell 
line, via retroviral transduction. MYCER consists of a full-
length MYC cDNA fused to the hormone-binding domain 
of the murine estrogen receptor. This ER fragment does 
not respond to estrogen [31]. Upon treatment with the 
synthetic ligand 4-hydroxytamoxifen (4OHT), MYCER 
protein is rapidly transported to the nucleus, rendering it 
active. 
Following retroviral transduction, we selected 
a clone expressing MYCER (Figure 1A) that fulfilled 
two criteria: 1) normal levels of endogenous MYC 
expression were retained, and 2) MYCER was expressed 
at levels 2-3 fold higher than endogenous MYC, a level 
of MYC expression that is appropriate for modeling 
MYC deregulation in human cancers without MYC 
amplification [32] (Figure 1A). Following 4OHT 
treatment, this clone showed a 1.54 fold increase in 
active, chromatin-bound MYCER, demonstrating 
the anticipated 4OHT-dependent nuclear import and 
activation of MYCER (Figure 1B). Next, we tested the 
ability of the MYCER transgene to activate transcription. 
MCF10A-MYCER cells were transfected with a luciferase 
reporter construct harboring tandem E-box sequences, 
the canonical MYC DNA binding site (Supplementary 
Figure 1). Upon 4OHT treatment, we observed a 2.3 fold 
increase in reporter activity (p<0.0001), consistent with 
the increase in chromatin-bound MYCER (Supplementary 
Figure 1). Finally, we tested the ability of the transgene 
to accelerate entry into S-phase, another hallmark of 
MYC deregulation. Cells were synchronized at the G1/S 
transition by double thymidine block and labeled with 
BrdU following induction of MYCER. S-phase entry was 
then monitored by the appearance of BrdU foci assessed 
by indirect immunofluorescence. As anticipated, MYCER 
induction triggered marked acceleration of S-phase entry 
(Figure 1C and Supplementary Figure 2). These results 
establish the validity of MCF10A-MYCER to model a 
near physiological degree of MYC deregulation.
Screen for synthetic lethal candidates with 
MYCER activation
Next, we performed a genome-wide screen to 
identify genes which loss is synthetic lethal with aberrant 
MYC expression utilizing the GIPZ Lentiviral Human 
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shRNA-mir Library (Thermo Scientific Open Biosystems, 
Waltham, MA, USA). The pooled shRNA plasmid library 
includes 58,493 shRNA constructs and targets 18,661 
known human genes (2-3 shRNAs per gene covering 75% 
of entire genome) as described in Rodriguez-Barrueco 
et al [33]. We designed the screen based on negative 
selection, i.e. we monitored loss of shRNAs to identify the 
corresponding genes that render cells sensitive to MYCER 
activation by 4OHT when lost (Figure 2A).
The screen was performed in 5 independent 
replicates, which were utilized to generate p-values for 
screening of statistically significant high-confidence 
candidates. Cells were initially transduced with the pooled 
shRNA library at 30% infection efficiency to achieve, on 
average, single-copy shRNA integration per cell. 200 
million cells were infected in order to obtain at least 
1000 cells with each shRNA from the library. Infected 
MCF10A-MYCER cells were first allowed to grow in 
the absence of MYCER induction for two generations 
to eliminate most shRNAs targeting essential genes. 
Then, the remaining cells were propagated in either the 
presence or absence of 4OHT for four weeks, maintaining 
a constant total cell number of at least 70 million per 
sample to preserve the representation of at least 1000 
cells per shRNA construct. The surviving populations 
were harvested after four weeks, and genomic DNA 
was isolated (Figure 2A). The stably integrated shRNA 
constructs were then amplified by large scale PCR, labeled 
with fluorescent nucleotides, and hybridized to custom 
microarrays harboring complementary oligonucleotide 
probes to the unique 60-nucleotide barcodes present on 
each individual shRNA. 
The microarray analysis was performed as described 
in Yu et al [34] (Figure 2B). We identified 78 candidate 
genes for which the corresponding shRNAs had a Log2FC 
(fold change) value of -1 or less, thus, depleted 2-fold 
or more in the MYC ON population compared to MYC 
OFF with a p-value of p<0.05 across five replicates 
(Supplementary Table 1). Functional annotation clustering 
using the KEGG pathways in the DAVID Bioinformatics 
Database revealed that the most represented biological 
pathways within the synthetic lethal candidates included 
ubiquitin mediated proteolysis, PPAR signaling pathway, 
fatty acid biosynthesis, fructose and mannose metabolism, 
and homologous recombination (Figure 2C). Within the 
proteolysis pathway and among the top hits we identified 
UBE2I, the E2 conjugating enzyme cooperating with the 
SAE1/2 E3 ligase in the SUMOylation pathway. This is 
in agreement with previous reports in which SAE1/2 and 
UBE2I were identified in similar MYC-synthetic lethal 
(MYC-SL) screens [29, 30]. Using a set of independent 
shRNAs, we validated that loss of UBE2I is indeed 
synthetic lethal with MYCER activation in MCF10A-
MYCER cells (p<0.0001), providing a proof of principle 
for our screen (Figures 2D and 2E). 
Notably, three major MYC-SL screens have been 
published to date [29, 30, 35]. When comparing our dataset 
to these screens, we observed that FBXW7 was one of 
four MYC-SL hits that overlapped between our screen and 
Kessler’s screen [29]. Additionally, the GSK3-β kinase, 
which is required for MYC degradation by FBXW7, was 
found as one of the eleven top MYC-SL kinases from 
Liu’s screen [12, 35]. Moreover, the MYC ubiquitination 
and SUMOylation network was determined as one of 
three major functional MYC-SL hubs, in a comprehensive 
meta-analysis of the three published MYC-SL datasets 
[36]. These results suggest that FBXW7-dependent MYC 
degradation may be a significant MYC-SL pathway. 
Figure 1: MCF10A-MYCER cells: a model for MYC deregulation. (A) MCF10A-MYCER cells express MYCER protein. 
Whole cell lysates from uninfected or MYCER-infected MCF10A cells were analyzed by SDS-PAGE. The positions of endogenous MYC 
and MYCER are indicated. (B) MYCER protein is activated in response to 4OHT treatment. Nuclear translocation of MYCER was analyzed 
by cell fractionation followed by SDS-PAGE of the chromatin-bound fraction from MCF10A-MYCER cells treated with vehicle or 200nM 
4OHT for 48 hr. MYCER increase was normalized to histone H3 levels for quantification. (C) MYCER activation induces accelerated entry 
into S phase. MCF10A-MYCER cells were arrested at G1/S with double thymidine. Cells were treated with vehicle (ethanol) or 4OHT, then 
pulse labeled with BrdU 1 hr after release into S phase. BrdU incorporation was assessed using indirect immunofluorescence. PI=propidium 
iodide was used to stain genomic DNA. 
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Therefore, we selected FBXW7 for further analysis, 
which ranked 58th in our high-confidence MYC-SL list 
with Log2FC=-1.1469 (p<0.02, Supplementary Table 1).
Loss of FBXW7 together with MYCER activation 
is lethal
We elected to further validate FBXW7, the substrate 
recognition subunit of the SCF-like E3 ubiquitin ligase 
complex that regulates degradation of MYC and other 
oncoproteins [14]. First, we wanted to confirm that 
loss of FBXW7 is lethal when combined with MYCER 
activation. We generated cell lines stably expressing 
either constitutively expressed or doxycycline-inducible 
shRNA clones targeting different regions of FBXW7 to 
experimentally manipulate its abundance. Following 
lentiviral infection of stable shRNA constructs and 
antibiotic selection, FBXW7 knockdown levels were 
assessed by quantitative RT-PCR. Both constitutive and 
doxycycline-inducible shRNA clones yielded an average 
of 45% knockdown of FBXW7 mRNA levels (Figure 3A). 
We were unable to achieve further knockdown of FBXW7 
in MCF10A-MYCER cells, suggesting a threshold level of 
FBXW7 is required for MCF10A-MYCER viability, even 
when the MYC transgene is off. 
We utilized a fluorescence-based cell competition 
assay to compare the viability of FBXW7 knockdown 
cells in the absence or presence of 4OHT over a period 
of approximately four weeks, to recapitulate the 
experimental conditions of the screen and physiological 
modest deregulation of MYC. Since all shRNA constructs 
co-express GFP or RFP, cells expressing shRNA are 
readily detectable by fluorescence. A mixed population 
of 50% MCF10A-MYCER cells without shRNA and 
Figure 2: Genome-wide screen for synthetic lethal candidates with MYCER activation. (A) Schematic diagram of screen 
design. See text for details. (B) Identification of synthetic lethal shRNA with MYCER. Heat map shows the relative enrichment or depletion 
of each shRNA in all experimental replicates (5 for MYC OFF and 5 for MYC ON). The spectrum between red and blue denote the relative 
representation of each shRNA barcode in the sample compared to the reference (library at T=0). (C) Five biological pathways most required 
for the survival of MCF10A-MYCER. Pathway analysis of the top synthetic lethal candidates (Log2 FC<-1) shows enrichment of genes in 
five biological pathways. Pathways are listed in order of number of genes appearing from the dataset. (D) UBE2I knockdown is synthetic 
lethal with MYCER activation. MCF10A-MYCER cells stably expressing two independent shRNA clones targeting UBE2I (shUBE2I-3 
and shUBE2I-6) were subjected to competitive survival assays. Fluorescence-based competition assay data are plotted as ratios of %GFP 
of MYC ON cells to MYC OFF cells at the given time points for cell lines stably expressing the indicated shRNA. Graph represents the 
average of three replicates (p<0.0001 between shCONTROL and shUBE2I-3, p<0.0001 between shCONTROL and shUBE2I-6). (E) 
shRNA-mediated stable knockdown of UBE2I. MCF10A-MYCER cells stably expressing shRNA clones targeting UBE2I (UBE2I-3 and 
UBE2I-6) were subjected to quantitative RT-PCR. Error bars represent the SEM of 3 independent experiments.
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50% MCF10A-MYCER cells infected with shFBXW7 
or shCONTROL were plated in MYC OFF or MYC ON 
conditions and continuously treated with vehicle or 4OHT 
at every passage. Cells were harvested at the indicated 
time points during the competition assay (Figures 3B 
and 3C), and subjected to live cell flow cytometry to 
measure the percentage of fluorescent surviving cells 
(Supplementary Figure 3). 
Both constitutive and inducible FBXW7 knockdown 
yielded a significant decrease in viability of cells treated 
with 4OHT expressing MYCER. Survival of cells infected 
with control shRNA was not significantly affected by 
MYCER induction over a period of 23 days, whereas 
cells with FBXW7 knockdown showed 11% less GFP 
signal in the presence of 4OHT by Day 23 (p=0.0006) 
(Figure 3B). When plotted as the MYC ON/MYC OFF 
ratio of surviving cells, we determined that the constitutive 
FBXW7 knockdown caused a 21% decrease in viability 
(p=0.0003), and the inducible knockdown clones resulted 
in an average of 53% decrease in viability compared to 
control cells (p<0.0001) (Figure 3C). The inducible clones 
likely yield a more robust reaction due to continuous 
induction of shRNA by 1μg/ml doxycycline addition at 
every passage.
Of note, all the shRNAs used in this secondary 
screen target different sequences within the FBXW7 
mRNA from the shRNAs included the library, confirming 
that the observed phenotype is due to FBXW7 down-
regulation. Taken together, these results validate the 
initial finding from our screen and establish that FBXW7 
knockdown is synthetic lethal with MYCER activation.
T47D breast tumor-derived cells are selectively 
sensitive to FBXW7 knockdown
Since we confirmed the synthetic lethal effect 
of FBXW7 knockdown with MYCER activation in 
MCF10A-MYCER cells, next we elected to examine 
the correlation between expression of FBXW7 and 
MYC in various breast tumor subtypes. Analysis of all 
breast tumors from The Cancer Genome Atlas (TCGA) 
database did not show any significant correlation 
between FBXW7 and MYC expression (data not shown). 
Intriguingly, however, we observed a modest, yet highly 
significant positive correlation between FBXW7 and 
MYC expression, exclusively in the Luminal A-subtype 
of breast cancers (rho=0.28, p=0.0004) (Figure 4A). 
Figure 3: Loss of FBXW7 combined with MYCER activation is lethal. (A) Knockdown of FBXW7 in MCF10A-MYCER cells. 
FBXW7 expression was inhibited in MCF10A-MYCER cells using lentiviral transduction of shRNA. Constitutive (FBXW7-7) (top panel) 
and inducible (FBXW7-8 and -10) (bottom panel) knockdown levels were analyzed by quantitative RT-PCR. Error bars represent the SEM 
of 3 independent experiments. (B) FBXW7 knockdown compromises the viability of MYC ON cells. Fluorescence-based competition 
assay over 23 days was performed as described in the text. The GFP-expressing population was measured at the indicated time points for 
untreated (NT) and 4OHT-treated cells. Cells were treated with vehicle or 4OHT every 72 hr for the duration of the experiments. Graphs 
represent the average of three replicates (NT vs 4OHT not significant for shCONTROL; p=0.0006 for shFBXW7-7). (C) Three independent 
clones of FBXW7 shRNA decrease the viability of 4OHT-induced MCF10A-MYCER cells. Fluorescence-based competition assay data 
are plotted as ratios of %GFP of MYC ON to MYC OFF at the given time points. Both constitutive (left panel) and inducible (right panel) 
FBXW7 knockdown clones show synthetic lethal effect with MYC activation. Graphs represent the average of three replicates (p=0.0003 
between shCONTROL and shFBXW7-7 in left panel; p<0.0001 for both shFBXW7-8 and shFBXW-10 in right panel).
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Luminal A breast cancers are the most prevalent subtype, 
accounting for approximately 40% of breast cancer cases 
[37]. Since this subtype is not normally associated with 
MYC overexpression, it is possible that Luminal A breast 
cancers retain sensitivity to MYC protein abundance, 
unlike MYC-independent breast cancer subtypes.
To expand our observation to another cell type 
and test if Luminal A-type cells are hypersensitive to 
FBXW7 knockdown, we achieved stable integration of 
doxycycline-inducible FBXW7 shRNA in the T47D breast 
cancer-derived cell line, which harbors a Luminal A-like 
signature (ER/PR-positive, Her2-negative, overexpresses 
luminal-specific cytokeratins 8 and 18). Continuous 
knockdown of FBXW7 over 30 days in T47D cells caused 
up to 41% decrease in viability compared to control 
(p=0.0076 and p=0.01 for shFBXW7-8 and shFBXW7-10, 
respectively, compared to shCONTROL) (Figures 4B and 
4C), consistent with our results in MCF10A-MYCER 
cells. We conclude from these observations that our initial 
findings from the screen using MCF10A-MYCER cells 
can be extended to the T47D breast cancer cell line in 
which MYC expression was not experimentally altered 
and independent of ER activation. 
FBXW7 knockdown specifically leads to 
stabilization of active MYCER 
To explore the mechanism by which FBXW7 
down-regulation leads to lethality in MYC expressing 
cells, we first sought to assess whether down-regulation 
of FBXW7 resulted in the stabilization of MYCER. To 
this end, we examined the cellular and chromatin-bound 
levels of MYCER upon FBXW7 knockdown. Total 
cellular levels of MYCER were significantly increased 
upon down-regulation of FBXW7 with either constitutive 
or inducible FBXW7 shRNAs (3.5 fold and 6.2 fold, 
respectively, p<0.05) (Figure 5A). Moreover, the levels 
of active, chromatin-bound MYCER detected upon cell 
fractionation [38] were synergistically increased upon 
FBXW7 knockdown and MYCER activation (Figure 5B). 
Chromatin-bound MYCER increased 2-5 fold upon 
FBXW7 down-regulation and further increased up to 10-
13.5 fold when MYCER was induced by 4OHT (p<0.1) 
(Figure 5B). To confirm if turnover of MYCER is affected 
by FBXW7 knockdown, we assessed total MYCER 
protein levels following cycloheximide treatment to 
prevent de novo MYCER synthesis in control or FBXW7 
knockdown conditions. We observed increased stability 
of MYCER upon FBXW7 down-regulation, indicative 
of reduced protein turnover (Figure 5C and 5D). These 
results suggest that FBXW7 knockdown significantly 
stabilizes deregulated MYCER, resulting in elevated 
levels of active chromatin-bound MYCER. 
As previously noted, FBXW7 controls the 
proteasome-dependent degradation of several cellular 
Figure 4: T47D breast cancer-derived cells are 
selectively sensitive to FBXW7 knockdown. (A) FBXW7 
and MYC expression levels positively correlate in Luminal 
A-type breast cancers. RNAseq (IlluminaHiSeq) data from 
TCGA breast invasive carcinoma dataset (TCGA_BRCA_exp_
HiSeqV2) were clustered using a “cluster of clusters” approach. 
Expression of MYC and FBXW7 in LUMINAL A subtypes were 
estimated in RSEM normalized count and Pearson correlation 
coefficient (rho) was calculated using STATA. (B) FBXW7 
knockdown decreases the viability of T47D cells. Fluorescence-
based competition assay data are plotted as ratios of MYC ON to 
MYC OFF at the given time points. All cells were continuously 
induced with 1μg/ml doxycycline at every passage during the 
assay. Error bars represent the SEM of 3 replicates (p=0.0076 
between shCONTROL and shFBXW7-8; p=0.01 between 
shCONTROL and shFBXW7-10). (C) Knockdown of FBXW7 
in T47D cells. FBXW7 expression was down-regulated in T47D 
cells using lentiviral transduction of shRNA. shRNA expression 
was induced by 1μg/ml doxycycline and FBXW7 mRNA levels 
were assessed by RT-PCR. Error bars represent the SEM of 3 
replicates.
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Figure 5: Loss of FBXW7 with MYCER activation results in specific stabilization of active MYCER protein. (A) 
MYCER protein stability is enhanced in FBXW7 knockdown cells. Whole cell extracts were prepared from MCF10A-MYCER cells with 
FBXW7 knockdown. Inducible clones were activated with 1μg/ml doxycycline. Quantified values below each lane are normalized to β 
actin and averaged for 3 experiments. Error bars represent the SEM. (B) Active MYCER is stabilized on chromatin in FBXW7 knockdown 
cells following 4OHT induction. Cells treated with vehicle or 4OHT were fractionated, and fraction P3 (chromatin-bound) was analyzed 
on SDS-PAGE. Quantifications are normalized to histone H3 and values are averages of 3 experiments. Error bars represent the SEM. (C) 
MYCER protein is stabilized upon FBXW7 knockdown. Indicated cell lines were treated with 200nM 4OHT and 1μg/ml doxycycline for 
24 h, then treated with 50μg/ml cycloheximide and harvested after 60 and 120 min. Whole cell lysates were run on SDS-PAGE. (D) Western 
blots from three independent experiments represented in (C) were normalized to β actin and quantified. Error bars represent the SEM. (E) 
FBXW7 knockdown with MYCER activation results in specific stabilization of MYCER. Whole cell extracts were prepared from control 
or FBXW7 knockdown cells and analyzed on SDS-PAGE followed by Western blot for FBXW7 targets (MYCER, c-Jun, Notch1, Cyclin 
E, mTOR). Quantifications show the fold enrichment of protein levels in control or FBXW7 knockdown cells normalized to β actin. Results 
are averages of 3 independent experiments and error bars represent the SEM. 
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oncogenes which could also be stabilized upon FBXW7 
knockdown and account for the observed phenotype [14]. 
Therefore, we examined the stability of other targets of 
FBXW7 by Western blot: c-Jun, NOTCH1, CyclinE, 
and mTOR, upon FBXW7 knockdown (Supplementary 
Figure 4). We find stabilization of MYCER, c-Jun, and 
CyclinE upon FBXW7 down-regulation in the absence 
of MYCER activation (Figure 5E, left). Notably, upon 
MYCER activation by 4OHT, only MYCER is stabilized 
when compared to the other FBXW7 targets examined 
(Figure 5E, right). Similar results were obtained using 
the inducible FBXW7 knockdown alleles (Supplementary 
Figure 5). These data suggest that FBXW7 knockdown in 
the context of MYCER activation leads predominantly to 
stabilization of MYCER. Our results point to the major 
role of FBXW7-mediated MYCER degradation for 
survival of cells with deregulated MYC.
MYCER stabilization results in accumulation of 
chromatin-bound CDC45 and cells in S/G2 phase
MYC deregulation triggers DNA damage and 
genomic instability [6, 39-41]. Therefore, we assessed 
the consequence of down-regulating FBXW7 together 
with MYCER activation on DNA damage and apoptosis. 
We monitored checkpoint activation (phosphorylation 
of Chk1 by ATR or Chk2 by ATM) and formation of 
DNA double strand breaks (phosphorylated H2AX), but 
could not detect a significant synergistic increase in these 
markers at any timepoint during the four week course 
of the experiments (Supplementary Figure 6A). Next, 
we probed for the apoptosis markers cleaved caspase-3, 
cleaved PARP, and PUMA, but did not detect significant 
changes by Western blotting (Supplementary Figure 6B). 
We then examined changes in cell cycle distribution. 
After four weeks of treatment with 4OHT, we found that 
FBXW7 knockdown cells in which MYC was deregulated 
Figure 6: MYCER stabilization results in accumulation of cells in S/G2 phase and chromatin-bound CDC45. (A) 
Constitutive knockdown of FBXW7 with MYCER activation results in additive accumulation of cells in S and G2/M phase. MCF10A-
MYCER cells with control or FBXW7 knockdown were cultured for 7 days in the absence or presence of 4OHT (MYC OFF or MYC 
ON). Cells were fixed and stained with propidium iodide for cell cycle analysis. Results are averages of 3 independent experiments and 
error bars represent the SEM. (B) Inducible knockdown of FBXW7 with MYCER activation results in accumulation of cells in S and 
G2/M phase. Control or FBXW7 knockdown cells were cultured for seven days with 1μg/ml doxycycline and vehicle or 4OHT every 72 
hr. Results are averages of 3 independent experiments and error bars represent the SEM. (C) Loss of FBXW7 with MYCER activation 
causes accumulation of CDC45 on chromatin. MCF10A-MYCER cells with control or FBXW7 knockdown were cultured for 7 days with 
or without 4OHT and fractionated. Fraction P3 was analyzed on SDS-PAGE. Shown is a representative image of CDC45 blot, and graph 
shows the average of 3 independent experiments each normalized to histone H3. Error bars represent the SEM.
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showed synergistic accumulation of cells in S phase and 
G2/M phase (p<0.05) (Figure 6A, 6B, and Supplementary 
Figure 7). These data suggest that aberrant expression of 
MYC resulted in slower S-phase progression and/or DNA 
replication stress, and these phenotypes are exacerbated 
with FBXW7 knockdown. 
We have recently demonstrated that MYC-
dependent DNA replication stress is directly mediated by 
CDC45, a component of the replicative DNA helicase that 
marks active origins of replication. We documented the 
distribution of chromosomal origins of DNA replication 
and found that MYC or CDC45 expression both altered 
their patterns in Xenopus extracts and in B cells [42]. 
To assess if the cell cycle phenotype we observed 
could be attributed to aberrant S-phase progression as a 
result of accumulation of active MYCER on chromatin, 
we monitored the levels of chromatin-bound CDC45 
in FBXW7 knockdown cells. We find that FBXW7 
knockdown in the context of MYCER activation by 4OHT 
results in a synergistic increase in the levels of chromatin-
bound CDC45 (6.7 fold increase, p<0.1), suggesting 
increased origin firing in the cells (Figure 6C). Our data 
suggest that FBXW7 knockdown cells with activated 
MYCER experience aberrant levels of origin firing during 
DNA replication, a sign of replication stress, which may 
contribute to the synthetic lethal phenotype.
DISCUSSION
Genome-wide screening utilizing RNAi has become 
a powerful tool to assess genetic interactions in human 
cells. Three screens specifically designed to identify 
genes required for cell survival upon MYC deregulation 
have been previously published [29, 30, 35]. Kessler et 
al. expressed MYCER in HMEC cells and performed a 
pooled retroviral shRNA screen [29], Toyoshima et al. used 
isogenic HFF cells with or without a MYC transgene and 
performed an siRNA screen [30], and Liu et al. performed 
a screen using siRNA against the human kinome in 
U2OS cells [35]. Intriguingly, when we compare the 78 
candidates from our screen to these datasets, less than 
5% of genes overlap in pairwise comparisons. Between 
ours and Kessler’s screen, four MYC-SL candidate genes 
overlap: FBXW7, LAMA2, PRMT8, and ZNF614 [29] 
(Supplementary Table 1). With Toyoshima’s screen [30], 
we observed one overlap, UBE2I, which we (Figure 2) 
and Kessler et al. have validated [29, 30] (Figures 2D and 
2E). With Liu’s screen, we did not observe any specific 
overlaps [35]. Several reasons may account for these 
differences. Different studies used normal or cancer cell 
lines. The mode of MYC deregulation (overexpression 
vs. inducible) and differences between siRNA and shRNA 
could also account for some differences. Furthermore, 
MYC regulates multiple cellular processes and its 
function as well as the impact of its expression depends 
heavily on the particular cellular context. Finally, it has 
been proposed that MYC acts as a general amplifier of 
activated transcription [43, 44], which could explain 
in part why MYC may be regulating the expression of 
different genes in different cell types. Thus, while the 
differences observed between datasets are puzzling, they 
demonstrate the importance of studying MYC biology 
within highly controlled and specific contexts that best 
mimic physiological systems. 
In the present study, we have identified 78 genes 
which down-regulation is synthetic lethal with MYCER 
activation in MCF10A-MYCER cells. Though our system 
utilizes a stably expressed fusion MYCER protein to model 
MYC deregulation, instead of endogenous MYC, previous 
studies have established that MYCER does not respond 
to estrogen and faithfully models MYC deregulation 
[31]. Nevertheless, we still cannot rule out that some of 
the MYC-SL candidates we identified may associate with 
cellular complexes not normally associated with MYC. 
Nevertheless, MYCER was shown to be a valid model 
for MYC deregulation in a screen that identified the 
SUMOylation machinery as a MYC-SL pathway using 
human mammary epithelial cells [29]. Moreover, we 
confirmed that T47D cells are hypersensitive to FBXW7 
knockdown in the absence of experimental modulation of 
MYC levels; further supporting the idea that MYCER is a 
valid model for MYC deregulation. 
We have validated FBXW7 as a gene which 
knockdown causes significantly decreased viability for 
cells with activated MYCER. Though FBXW7 is known 
to target several oncogenes for degradation, our findings 
indicate that knockdown of FBXW7 in the presence of 
MYCER activation causes preferential stabilization of 
MYCER. Our data suggest that stabilization of MYCER 
is critical to cause increased accumulation of FBXW7 
knockdown cells in S/G2 phase and loss of viability. 
Of note, we were not able to detect significant levels of 
DNA damage or apoptosis markers at any given time 
throughout the course of the competition assays. This may 
be attributed to the slow and gradual nature of cell death 
induction in our experiments, mimicking physiological 
conditions. We observe, at most, 50% decrease in viability 
of FBXW7 knockdown cells compared to control cells 
over the course of four weeks. We believe that at any given 
time point, only a small fraction of cells is expressing 
markers of DNA damage or apoptosis, which is in contrast 
to what is seen following acute MYC overexpression. 
Nevertheless, the possibility of senescence or alternative 
cell death pathway activation cannot be excluded.
FBXW7 is one of only four MYC-SL candidate 
genes that were identified from both our screen and 
Kessler’s screen, emphasizing its potential significance 
as a major MYC-SL pathway [29] (Supplementary Table 
1). The two other MYC-SL datasets did not include 
FBXW7, however, the smaller RNAi libraries utilized 
in these screens may not have included FBXW7 [30, 
35]. Notably, Liu’s screen that interrogated the human 
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kinome identified GSK3-β, the kinase responsible for a 
MYC phosphorylation that is required for recognition by 
FBXW7 [12, 35]. While it has been very challenging to 
identify common MYC-SL genes and pathways across 
available datasets[36], these findings suggest that the 
FBXW7-dependent MYC degradation pathway may be a 
bona fide MYC-SL pathway shared by multiple cell types.
It is well established that FBXW7 is a crucial 
component of the SCF-like ubiquitin ligase complex, 
which targets poly-ubiquitinated proteins for proteasomal 
degradation. Since many targets of FBXW7 are oncogenes 
such as MYC, CyclinE, NOTCH1, and c-JUN, FBXW7 
is generally considered a tumor suppressor gene. In fact, 
in human T-cell acute lymphoblastic leukemia (T-ALL), 
FBXW7 is one of the most frequently mutated genes 
(approximately 30% of cases [45]) and mouse models 
with tissue specific knockout of FBXW7 in various 
settings develop both hematopoietic and solid tumors [46], 
corroborating the tumor suppressing functions of FBXW7 
in these contexts. 
We propose that FBXW7 can also act as a tumor 
maintenance gene in the context of MYC deregulation. For 
cells expressing MYC at aberrant levels, the presence of 
FBXW7 enables their continued proliferation and survival. 
Consistent with our results, increased accumulation of 
MYC is responsible for the loss of leukemic stemness in 
leukemia-initiating cells lacking FBXW7 [47-49]. In a 
T-ALL mouse model, MYC protein levels in leukemia-
initiating cells were found to be heavily dependent on 
FBXW7 activity, demonstrating that MYC is the major 
contributor to the FBXW7 phenotype [49]. In agreement, 
our studies suggest that accumulation of active MYC 
protein is the major contributor to the synthetic lethal 
phenotype seen upon FBXW7 knockdown and MYCER 
activation. Though we have not tested other documented 
targets of FBXW7 such as SREBP, p100, NRF1, NF1, 
Mcl-1, KLF5, c-Myb, and Aurora A [46], our results 
strongly suggest that MYCER is the critical target of 
FBXW7 contributing to the synthetic lethal phenotype in 
MYCER activated cells. 
While FBXW7 mutations are found in 
several diverse human cancer types such as T-ALL, 
cholangiocarcinoma, stomach, colon, pancreas, and 
endometrium, they are rare in other cancers [50]. In fact, 
according to Akhoondi et al. [18], FBXW7 mutations 
appear to be infrequent in breast and ovarian cancers. 
This could be explained in part by our results suggesting 
that inactivating mutations of FBXW7 may not be able to 
coexist with MYC overexpression in the breast context. 
Interestingly, our analysis suggests that MYC and 
FBXW7 expression are mildly but significantly positively 
correlated, specifically in the Luminal A-subtype of breast 
cancers. Notably, this subtype is typically associated with 
low to normal MYC expression, suggesting that cells 
retain physiological regulation of MYC abundance [51]. 
This is in contrast to cells derived from breast cancer types 
with MYC overexpression, which can be unresponsive to 
MYC suppression [52]. Breast cancer cells with low MYC 
expression, such as Luminal A, may be more sensitive to 
small fluctuations in MYC protein levels which arise from 
altered FBXW7 expression.
To gain further insight into the relationship between 
FBXW7 and MYC in breast, further studies are critical. 
Nevertheless, our results demonstrating the identification 
of FBXW7 as a synthetic lethal target in the context of 
MCF10A-MYCER adds insight to the still enigmatic role 
of the interaction between FBXW7 and MYC in human 
cancer initiation, progression, and maintenance. 
MATERIALS AND METHODS
Isolation of MYCER cells
MYCER was introduced retrovirally using pBabe-
hygro-MYCER into MCF10A cells and transduced clones 
were selected by the addition of 100цg/ml Hygromycin 
B (Roche Holding AG, Basel, Switzerland). Clones were 
isolated by serial dilution. 
Production of lentivirus and shRNA 
Glycerol stocks of lentiviral shRNA constructs 
(pGIPZ, pTRIPZ) were obtained from Thermo 
Scientific Open Biosystems (Waltham, Massachusetts, 
USA) and grown in LB medium with 100цg/ml 
carbenicillin (Sigma) and 25цg/ml Zeocin (InvivoGen, 
San Diego, CA, USA). Clones used were FBXW7-7 
(V2LHS_202932), FBXW7-8 (V2THS_89328), FBXW7-
10 (V2THS_203045), UBE2I-3 (V2LHS_171776), and 
UBE2I-6 (V3LHS_376933). Plasmids were isolated using 
the E.Z.N.A. Plasmid Miniprep kit (Omega Bio-Tek, Inc., 
Norcross, GA, USA) and packaged into lentivirus by 
transfecting (jetPEI by Polyplus-transfection S.A., Illkirch, 
France) into 293T cells with pMD.G and pCMVR8.91. 
Viruses were collected in MCF10A media, filtered, 
and infected into MCF10A in the presence of 8цg/ml 
polybrene (Sigma) and spin infected for 1 hr at 1000rpm at 
RT. After 24 hr of incubation, infected cells were selected 
by the addition of 2цg/ml puromycin (Sigma). 
Cell culture
MCF10A cells were cultured in DMEM/F12 
(Invitrogen, Carlsbad, CA, USA) supplemented with 
5% horse serum (Invitrogen), 20ng/ml EGF (Peprotech, 
Rocky Hill, NJ, USA), 0.5цg/ml hydrocortisone (Sigma-
Aldrich Corporation, St. Louis, MO, USA), 100ng/ml 
cholera toxin (Sigma), 10цg/ml insulin (Sigma), and 
antibiotics. T47D and 293T cells were cultured in DMEM 
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(Invitrogen) supplemented with 10% FBS (Invitrogen) and 
antibiotics. All cells were incubated at 37ºC and 5% CO2. 
Cell lysis and cellular fractionation
Cells were lysed in RIPA buffer (150mM NaCl, 
1% NP40, 0.5% DOC, 0.1% SDS, 50mM Tris pH 8.0), 
supplemented with protease and phosphatase inhibitors 
(Sigma), for 15 min on ice. Samples were sonicated (2 
x 5 min) and centrifuged for 10 min at 4ºC. Cellular 
fractionation was performed as published by Mendez and 
Stillman[38]. 
shRNA screen
The pooled shRNA screen was carried out using 
the Thermo Scientific Open Biosystems GIPZ Lentiviral 
Human shRNA-mir Library as described in Rodriguez-
Barrueco et al [33]. The library was packaged into 
lentivirus as described above, and MCF10A-MYCER 
cells were infected at 30% efficiency. Infected cells were 
selected with 2цg/ml puromycin for two passages and 
divided into 10 independent populations. Five populations 
were treated with 200nM 4OHT (every 48 hr) and five 
were treated with vehicle. After 30 days, genomic DNA 
of surviving cells was isolated by lysing cells with DNA 
lysis buffer (1% SDS, 100mM EDTA pH8.0, 50mM 
Tris-HCl pH8, 100nM NaCl), treating with RNAse A 
(Qiagen N.V., Venlo, Netherlands), and purifying DNA 
with phenol chloroform extraction and isopropanol 
precipitation. Resulting DNA was subjected to PCR to 
recover the shRNA and associated barcodes, generating a 
heterogeneous pooled product of approximately 350 bps. 
The PCR product was gel-extracted and purified, labeled 
with Cy3 and Cy5 (Roche), and hybridized to customized 
microarrays (Agilent Technologies, Inc., Santa Clara, CA, 
USA) harboring complementary probes to the shRNA 
barcodes. Data analysis was then performed as described 
in Yu et al [34].
mRNA isolation and RT-PCR
RNA was isolated using the Nucleospin RNA II 
kit (Clontech Laboratories, Inc., Mountain View, CA, 
USA). 1μg of RNA was subjected to reverse transcription 
using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Life Technologies, Carlsbad, CA, 
USA). cDNA was used as template for quantitative RT-
PCR using ABsolute Blue QPCR SYBR Green Low ROX 
Mix (Thermo Scientific) and Applied Biosystems 7500 
Fast (Life Technologies, Carlsbad, CA, USA).
Competition assays
250 000 MCF10A-MYCER cells expressing stably 
integrated shRNA and 250 000 MCF10A-MYCER 
cells without shRNA were plated together. At the first 
passage, fluorescent cells were counted by live cell flow 
cytometry, and replated with either vehicle or 4OHT. 
At each subsequent passage, remaining percentage of 
fluorescent cells was analyzed using flow cytometry. All 
cell sorting was performed with the BD FACSCalibur (BD 
Biosciences, San Jose, CA, USA).
Luciferase assay
MCF10A-MYCER cells were plated in 12-
well plates. After 24 hr, at 90% confluence, they were 
transfected with MYC reporter and Renilla plasmid and 
incubated for 48 hr with or without 4OHT. Using the Dual-
Luciferase Reporter Assay System (Promega Corporation, 
Fitchburg, WI, USA), relative luciferase activity was 
measured with the GloMax Luminometer (Promega). 
Double thymidine block and indirect 
immunofluorescence
MCF10A-MYCER cells were plated on sterilized 
coverslips. After 24 hr, cells were incubated in 2.5mM 
thymidine for 17 hr. After a 7 hr recovery, the second 
block was administered at 2.5mM for 14 hr. Vehicle 
or 4OHT was added 3 hr prior to release. After 1 hr 
recovery, cells were treated with an 8 min pulse of 33цM 
BrdU. Immediately, cells were washed and fixed with 
4% paraformaldehyde for 15 min at RT, washed, then 
permeabilized with 0.2% Triton-X in PBS for 5 min and 
washed. DNA was denatured in 2N HCl for 20 min at RT, 
following neutralization with 0.1M sodium tetraborate 
pH8.5. Primary antibody incubation with anti-BrdU 
(#555647, BD Pharmingen, San Jose, CA, USA) was 
performed in PBS-0.5%Tween for 30 min at RT, followed 
by washing, and secondary antibody incubation with goat-
anti-mouse-FITC (Jackson ImmunoResearch Laboratories, 
Inc., West Grove, PA, USA) was performed in PBS-
0.5%Tween for 30 min. Cells were washed and stained 
for 1 min with propidium iodide, airdried, and mounted on 
slides for confocal microscopy. The Zeiss LSM 510 Meta 
Inverted (Carl Zeiss AG, Oberkochen, Germany) was used 
for all confocal imaging.
Western blotting and quantification
Cell lysates were prepared as described, added to 
5X Laemmli buffer and heated at 95ºC for 5 min. Samples 
were run on Tris-Glycine or NuPAGE Tris-Acetate gels 
(Invitrogen) and transferred to PVDF membranes at 35V 
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for 2 hr. Membranes were blocked in PBS-0.5%Tween-
5%milk for 1 hr and stained with primary antibodies 
(1:250-1:2000) for 1 hr or overnight, followed by staining 
with secondary antibodies (1:10,000) conjugated with 
HRP (Jackson) for 1 hr. After incubation with ECL 
(Pierce, Thermo Fisher Scientific), blots were exposed to 
film. ImageQuant 5.2 (Molecular Dynamics) was used for 
quantification.
mRNA expression analysis
RNAseq (IlluminaHiSeq) data from TCGA breast 
invasive carcinoma dataset was downloaded from 
the cancer browser (TCGA_BRCA_exp_HiSeqV2). 
Overall, 160 samples with RNAseq data were previously 
classified as LUMINAL A subtype according to the 
integrative multiplatform approach described in Nature 
2012 (PMID:23000897). Briefly, breast tumors were 
clustered using a “cluster of clusters” approach based 
on miRNAs, DNA methylation, copy number, PAM50 
mRNA expression, and RPPA expression data. Expression 
of MYC and FBXW7 in LUMINAL A subtypes were 
estimated in RSEM normalized count and Pearson 
correlation coefficient (rho) was calculated using STATA 
(Stata Statistical Software: Release 12. College Station, 
TX: StataCorp LP).
Cell cycle analysis
At the time of harvest, MCF10A-MYCER cells 
were vortexed in 0.5 ml PBS, and 5 ml of 70% ethanol 
was added dropwise for fixing at -20ºC overnight. The 
next day, cells were incubated in 1 ml PBS for 1 hr on 
ice and centrifuged. To the resulting pellet, RNAse A 
was added at 1/400, and propidium iodide stock (10mg/
ml, Sigma) was added at 1/1000 for flow cytometry. All 
analysis was performed with the BD FACSCalibur (BD 
Biosciences).
Antibodies
The following antibodies were used for 
immunostaining: MYC (9E10, Santa Cruz Biotechnology, 
Inc., Dallas, TX, USA), c-Jun (sc-44, Santa Cruz), cleaved 
Notch1 (4147, Cell Signaling, ), cyclin E (sc-481, Santa 
Cruz Biotech), mTOR (2972, Cell Signaling Technology, 
Inc., Danvers, MA, USA), βactin (A2228, Sigma), Histone 
H3 (9715, Cell Signaling), Cdc45 (EPR5759, Epitomics, 
Burlingame, CA, USA), Phospho-Chk2 (2661, Cell 
Signaling), Phospho-H2AX (JBW301, EMD Millipore, 
Billerica, MA, USA), Cleaved Caspase-3 (9664, Cell 
Signaling), PARP-1 (sc-8007, Santa Cruz), PUMA (sc-
28226, Santa Cruz).
Statistics
All statistical values represented in figures were 
generated through appropriate t-tests (paired, unpaired, 
one-sample or two-sample) using Prism 5 (GraphPad 
Software, La Jolla, CA, USA).
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